NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS

NYX-2925, A NOVEL, NON-OPIOID, SMALL-MOLECULE MODULATOR OF THE N-METHYL-d-ASPARTATE RECEPTOR (NMDAR), DEMONSTRATES POTENTIAL TO TREAT CHRONIC, SUPRASPINAL CENTRALIZED PAIN CONDITIONS

Pain is both a sensory and emotional experience, which serves an adaptive purpose by protecting the body from prolonged and repeated tissue damage. However, the presence of chronic pain can transition to a maladaptive state leading to life-long suffering and is currently a health care burden due to...

Full description

Bibliographic Details
Main Authors: Jessica Marie Gajda, MS, Marina Asiedu, PhD, Gladys Morrison, PhD, Jacqueline Ann Dunning, Nayereh Ghoreishi-Haack, MS, Amanda Lynn Barth, PhD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Medicine in Drug Discovery
Subjects:
N-methyl-D-aspartate receptor modulation
Centralized pain
Chronic constriction injury (CCI)
Diabetic peripheral neuropathy
Chemotherapeutic-induced neuropathy
Analgesia
Online Access:http://www.sciencedirect.com/science/article/pii/S2590098620300543

Internet

http://www.sciencedirect.com/science/article/pii/S2590098620300543

Similar Items